• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Merck, BMS to conduct phase II trial of MK-5172, daclatasvir for hep C

Merck, BMS to conduct phase II trial of MK-5172, daclatasvir for hep C

April 22, 2013
CenterWatch Staff

Global healthcare company Merck has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of BMS’s investigational NS5A replication complex inhibitor, daclatasvir, and Merck's investigational NS3/4A protease inhibitor, MK-5172, for the treatment of chronic hepatitis C virus (HCV) infection, genotype 1.

The planned initiation of the phase II clinical trial follows the completion of a phase I safety evaluation of the investigational combination regimen. Merck will conduct the phase II clinical trial. Further clinical development activities beyond the phase II study are not covered as part of this agreement.

"In HCV, agreements like this that combine novel investigational candidates are important to evaluate the potential of novel oral regimens early in the development cycle," said Eliav Barr M.D., vice president, infectious diseases, project leadership and management, Merck Research Laboratories. "We are pleased to collaborate with Bristol-Myers Squibbto advance this potential all-oral combination."

Additional details of the collaboration were not disclosed.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing